Drug Trial Radar · NCT01659866
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Last checked: Nov 19, 2026Latest source record: Jun 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
563
Actual
Start
Aug 2012
Primary completion
Aug 2015
Study completion Aug 2016
Sponsor
- Lead sponsor
- Northwestern UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 8, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 30 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being conducted in men scheduled to undergo transrectal ultrasound-guided prostate biopsy (TRUSP). Traditionally prior to prostate biopsy, an antibiotic, ciprofloxacin, has been given to men to prevent biopsy-related infections. In recent years as ciprofloxacin resistance has increased in the community, more and more men are becoming infected with ciprofloxacin-resistant bacteria after prostate biopsy. This study is being done to determine if obtaining rectal swab cultures and choosing antibiotics based on these culture results will result in fewer infectious complications than giving all men ciprofloxacin. The investigators will compare 2 groups: men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy, and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative antibiotics based on their culture results. Our hypothesis is that these 2 groups will have equal numbers of post-biopsy infectious complications and both groups will have fewer infectious complications than a historical group who received empiric ciprofloxacin without the benefit of rectal swab culture results.
Conditions
- Infection
Interventions
CiprofloxacinDrug
500 mg orally 2 hours before prostate biopsy
trimethoprim-sulfamethoxazoleDrug
1 double strength tablet orally 2 hours before the procedure and again 12 hours later
cefuroximeDrug
500 mg orally 2 hours before the procedure then again 12 hours later
ceftriaxoneDrug
500 mg intramuscularly 2 hours before the procedure
gentamicinDrug
2 mg/kg intramuscularly 2 hours before the procedure
amikacinDrug
5 mg/kg intramuscularly 2 hours before the procedure
aztreonamDrug
500 mg intramuscularly 2 hours before the procedure
imipenemDrug
500 mg intramuscularly 2 hours before the procedure
ceftriaxoneDrug
2000 mg intravenously 1 hour before the procedure
gentamicinDrug
2 mg/kg intravenously 1 hour before the procedure
amikacinDrug
5 mg/kg intravenously 1 hour before the procedure
aztreonamDrug
2000 mg intravenously 1 hour before the procedure
imipenemDrug
1000 mg intravenously 1 hour before the procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Post-biopsy Infection.Time frame: 30 days post-biopsy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwestern University Department of Urology
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.